PCS
ABBV icon

Personal CFO Solutions’s AbbVie ABBV Stock Holding History

Personal CFO Solutions’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Sell
5,854
-568
-9% -$126K 0.18% 99
2025
Q4 		$1.47M Buy
6,422
+141
+2% +$32.1K 0.23% 72
2025
Q3 		$1.45M Sell
6,281
-185
-3% -$37.7K 0.26% 73
2025
Q2 		$1.2M Sell
6,466
-881
-12% -$164K 0.22% 87
2025
Q1 		$1.54M Sell
7,347
-171
-2% -$33.2K 0.31% 64
2024
Q4 		$1.34M Sell
7,518
-3,797
-34% -$698K 0.26% 72
2024
Q3 		$2.23M Sell
11,315
-62
-0.5% -$11.6K 0.31% 63
2024
Q2 		$1.95M Buy
11,377
+48
+0.4% +$7.95K 0.3% 64
2024
Q1 		$2.06M Buy
11,329
+302
+3% +$52K 0.32% 61
2023
Q4 		$1.71M Buy
11,027
+4,738
+75% +$691K 0.3% 63
2023
Q3 		$938K Buy
6,289
+485
+8% +$71.2K 0.19% 105
2023
Q2 		$782K Sell
5,804
-98
-2% -$14.4K 0.16% 127
2023
Q1 		$941K Buy
5,902
+319
+6% +$48.8K 0.19% 97
2022
Q4 		$902K Buy
5,583
+413
+8% +$63.3K 0.19% 101
2022
Q3 		$694K Buy
5,170
+147
+3% +$21.1K 0.17% 113
2022
Q2 		$769K Buy
5,023
+216
+4% +$33K 0.18% 98
2022
Q1 		$779K Buy
4,807
+636
+15% +$92.4K 0.15% 129
2021
Q4 		$565K Sell
4,171
-1,340
-24% -$158K 0.11% 180
2021
Q3 		$595K Buy
5,511
+1,553
+39% +$177K 0.12% 163
2021
Q2 		$446K Buy
3,958
+40
+1% +$4.5K 0.09% 206
2021
Q1 		$424K Sell
3,918
-489
-11% -$52.3K 0.09% 203
2020
Q4 		$472K Sell
4,407
-166
-4% -$16K 0.12% 171
2020
Q3 		$0 Buy
4,573
+334
+8% +$31.4K ﹤0.01% 135
2020
Q2 		$416K Sell
4,239
-1,562
-27% -$138K 0.12% 158
2020
Q1 		$442K Buy
5,801
+3,035
+110% +$259K 0.16% 135
2019
Q4 		$245K Hold
2,766
– – 0.07% 269
2019
Q3 		$209K Buy
+2,766
New +$190K 0.08% 262

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Personal CFO Solutions's ABBV Position: Q1 2026 in Review

Personal CFO Solutions reduced its AbbVie (ABBV) stake by 8.8% in Q1 2026, selling an estimated $126K and leaving 5,854 shares worth $1.27M. The position accounts for 0.18% of the portfolio, ranked #99.

Personal CFO Solutions first reported a position in ABBV in Q3 2019 and has held it in 27 quarters since. The position peaked at $2.23M in Q3 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Personal CFO Solutions held 5,854 shares of AbbVie worth $1.27M as of Q1 2026.
  • Personal CFO Solutions sold 568 AbbVie shares in Q1 2026, an estimated $126K.
  • AbbVie made up 0.18% of Personal CFO Solutions's portfolio in Q1 2026, its #99 holding.
  • Personal CFO Solutions first reported a position in AbbVie in Q3 2019 and has held it in 27 quarters since.
  • Personal CFO Solutions's AbbVie position peaked at $2.23M in Q3 2024.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Personal CFO Solutions's 13F filing for Q1 2026, filed 30 Apr 2026.